Cargando…

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakasis, Athanasios-Dimitrios, Bitzogli, Kleopatra, Mouziouras, Dimitrios, Pouliakis, Abraham, Roumpoutsou, Maria, Goules, Andreas V., Androutsakos, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/
https://www.ncbi.nlm.nih.gov/pubmed/35215801
http://dx.doi.org/10.3390/v14020207
_version_ 1784658297160204288
author Bakasis, Athanasios-Dimitrios
Bitzogli, Kleopatra
Mouziouras, Dimitrios
Pouliakis, Abraham
Roumpoutsou, Maria
Goules, Andreas V.
Androutsakos, Theodoros
author_facet Bakasis, Athanasios-Dimitrios
Bitzogli, Kleopatra
Mouziouras, Dimitrios
Pouliakis, Abraham
Roumpoutsou, Maria
Goules, Andreas V.
Androutsakos, Theodoros
author_sort Bakasis, Athanasios-Dimitrios
collection PubMed
description The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination.
format Online
Article
Text
id pubmed-8876976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88769762022-02-26 Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases Bakasis, Athanasios-Dimitrios Bitzogli, Kleopatra Mouziouras, Dimitrios Pouliakis, Abraham Roumpoutsou, Maria Goules, Andreas V. Androutsakos, Theodoros Viruses Brief Report The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. MDPI 2022-01-21 /pmc/articles/PMC8876976/ /pubmed/35215801 http://dx.doi.org/10.3390/v14020207 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Bakasis, Athanasios-Dimitrios
Bitzogli, Kleopatra
Mouziouras, Dimitrios
Pouliakis, Abraham
Roumpoutsou, Maria
Goules, Andreas V.
Androutsakos, Theodoros
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title_full Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title_fullStr Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title_full_unstemmed Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title_short Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
title_sort antibody responses after sars-cov-2 vaccination in patients with liver diseases
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/
https://www.ncbi.nlm.nih.gov/pubmed/35215801
http://dx.doi.org/10.3390/v14020207
work_keys_str_mv AT bakasisathanasiosdimitrios antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT bitzoglikleopatra antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT mouziourasdimitrios antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT pouliakisabraham antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT roumpoutsoumaria antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT goulesandreasv antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases
AT androutsakostheodoros antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases